NCT02722954 - A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

May 10, 2017

Study Completion Date

May 19, 2017

Conditions

Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

Demcizumab

Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).

DRUG

Pembrolizumab

Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks

Trial Locations (6)

Columbia University Medical Center, New York

Sarah Cannon Research Institute, Nashville

The START Center for Cancer Care, San Antonio

Rocky Mountain Cancer Center, Denver

University of Michigan Health System, Ann Arbor

The Royal Marsden NHS Foundation Trust, Sutton